Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample
Verified February 2014 by Stanford University
Information provided by (Responsible Party):
First received: December 4, 2007
Last updated: February 14, 2014
Last verified: February 2014
The goal of this study is to study NIS expression in benign and malignant breast and thyroid samples using archival formalin-fixed paraffin-embedded tissue sections.
Salivary Gland Neoplasms
||Observational Model: Cohort
Time Perspective: Retrospective
||Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival and Frozen Human Tissue Samples
Biospecimen Retention: Samples Without DNA
Cases will be identified from clinic patient medical records and linked to pathology reports. The surgical pathology record number will thus be obtained and used to retrieve the archival blocks and slides. Approximately three representative blocks will be selected and 4-6 four micron thick sections will be cut on a microtome. Cases with limited archived diagnostic material will not be selected nor blocks where there is little materials.
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||December 2016 (Final data collection date for primary outcome measure)
The objective of the study is to further understanding of proteins that occur in both normal cells and tumor cells and to learn more about certain diseases and potential alternative treatments for these diseases.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Cases will be identified from clinic patient medical records and linked to pathology reports. The surgical pathology record number will thus be obtained and used to retrieve the archival blocks and slides. In addition, all these participants will be clinical patients of the Protocol Director, thus the Physician will always be familiar with the participants.
- Patient must be over the age of 18.
- Patients must have benign and malignant breast and thyroid cancer.
- Patient mus sign consent form.
1. No children will be allowed.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00568438
|Stanford University School of Medicine
|Stanford, California, United States, 94305 |
|Contact: Donna Adelman 650-724-1953 email@example.com |
|Contact: Cancer Clinical Trials Office (650) 498-7061 |
|Principal Investigator: Irene L. Wapnir |
|Sub-Investigator: Ralph S. Greco MD |
|Sub-Investigator: Kent W Nowels |
||Irene L. Wapnir
No publications provided
History of Changes
|Other Study ID Numbers:
||BRSNSTU0011, 75622, 11005
|Study First Received:
||December 4, 2007
||February 14, 2014
||United States: Food and Drug Administration
United States: Institutional Review Board
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 27, 2015
Salivary Gland Neoplasms
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Head and Neck Neoplasms
Neoplasms by Site
Salivary Gland Diseases